GlaxoSmithKline plc (LON:GSK) had its price target lowered by Berenberg Bank from GBX 1,885 ($24.55) to GBX 1,835 ($23.90) in a report published on Wednesday. The firm currently has a buy rating on the stock.
Several other equities analysts have also commented on the company. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.74) price target on GlaxoSmithKline plc and gave the stock a buy rating in a research report on Tuesday. Deutsche Bank AG set a GBX 1,610 ($20.97) price objective on GlaxoSmithKline plc and gave the stock a neutral rating in a report on Tuesday. UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc and gave the stock a neutral rating in a report on Tuesday, August 1st. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a report on Friday, July 28th. Finally, Morgan Stanley set a GBX 1,700 ($22.14) price objective on GlaxoSmithKline plc and gave the stock a neutral rating in a report on Thursday, July 27th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of GBX 1,724 ($22.45).
GlaxoSmithKline plc (GSK) opened at 1475.00 on Wednesday. The firm has a 50-day moving average of GBX 1,589.13 and a 200 day moving average of GBX 1,623.61. The stock’s market capitalization is GBX 72.10 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,446.50 and a 52 week high of GBX 1,745.56.
WARNING: “GlaxoSmithKline plc (LON:GSK) Given New GBX 1,835 Price Target at Berenberg Bank” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/12/glaxosmithkline-plc-longsk-given-new-gbx-1835-price-target-at-berenberg-bank.html.
The company also recently declared a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a yield of 1.23%.
In other news, insider Patrick Vallance purchased 861 shares of the business’s stock in a transaction on Friday, July 14th. The stock was purchased at an average price of GBX 1,618 ($21.07) per share, with a total value of £13,930.98 ($18,141.66). Also, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction on Wednesday, July 26th. The stock was purchased at an average cost of GBX 1,599 ($20.82) per share, with a total value of £36,249.33 ($47,205.80). In the last ninety days, insiders acquired 3,151 shares of company stock valued at $5,054,922.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.